Literature DB >> 17051205

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.

Michael T Lin1, M Flint Beal.   

Abstract

Many lines of evidence suggest that mitochondria have a central role in ageing-related neurodegenerative diseases. Mitochondria are critical regulators of cell death, a key feature of neurodegeneration. Mutations in mitochondrial DNA and oxidative stress both contribute to ageing, which is the greatest risk factor for neurodegenerative diseases. In all major examples of these diseases there is strong evidence that mitochondrial dysfunction occurs early and acts causally in disease pathogenesis. Moreover, an impressive number of disease-specific proteins interact with mitochondria. Thus, therapies targeting basic mitochondrial processes, such as energy metabolism or free-radical generation, or specific interactions of disease-related proteins with mitochondria, hold great promise.

Entities:  

Mesh:

Year:  2006        PMID: 17051205     DOI: 10.1038/nature05292

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  2000 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

2.  Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation.

Authors:  Wei-Jin Fang; Chun-Jiang Wang; Yang He; Yu-Lu Zhou; Xiang-Dong Peng; Shi-Kun Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 3.  Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration.

Authors:  Jorge M A Oliveira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 4.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

5.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

6.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 8.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

Review 9.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

10.  Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.

Authors:  Tao Ma; Xueliang Du; Joseph E Pick; Guangzhi Sui; Michael Brownlee; Eric Klann
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.